The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BRAF mutation as a pejorative marker in metastatic melanoma.
Sophie Brissy
No relevant relationships to disclose
Caroline Gaudy-Marqueste
No relevant relationships to disclose
Stéphanie Mallet
No relevant relationships to disclose
Sandrine Monestier
No relevant relationships to disclose
Sylvie Hesse
No relevant relationships to disclose
Marie-Christine Koeppel
No relevant relationships to disclose
Marie-Christine Rojat-Habib
No relevant relationships to disclose
Isabelle Nanni
No relevant relationships to disclose
Anderson Loundou
No relevant relationships to disclose
L'houcine Ouafik
No relevant relationships to disclose
Nathalie Bonnet
No relevant relationships to disclose
Marie-Aleth Richard
Other Remuneration - Roche/Genentech
Jean Jacques Grob
Consultant or Advisory Role - Roche/Genentech
Honoraria - GlaxoSmithKline; Roche/Genentech